Ambu A/S : upgraded in MSCI ESG rating

Ambu recently received an MSCI ESG Rating of AA.

MSCI is an American finance company that services institutional investors around the world. MSCI research and rate companies on a scale from 'CCC' to 'AAA' according to their exposure to industry-material ESG risks and their ability to manage those risks relative to peers.

In the 2021 rating of Ambu, we are upgraded from 'A' to 'AA', which is the second highest score placing us in the top 20% of medtech peers.

Key issues
The MSCI analysis identifies four key issues for Ambu's ESG profile and compares them with the industry standard for medtech companies. The issues are Human Capital Development, Carbon Emissions, Governance and Product Safety & Quality.

"I'm happy that we get credit for some of the really solid work that Ambu has done for many years on product safety and quality management which we in the past may not have communicated in a clear enough way to our external stakeholders," says Lene Møldrup, Director of ESG at Ambu.

"Also, MSCI has noted that our ethics framework now includes a detailed anti-bribery policy, and that we became a signatory to the UN Global Compact in 2020. These recent efforts also contribute to the upgrade in our ESG rating."

DISCLAIMER STATEMENT
THE USE BY AMBU A/S OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES ("MSCI") DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF AMBU A/S BY MSCI. MSCI SERVICES AND DATA ARE THE PROPERTY OF MSCI OR ITS INFORMATION PROVIDERS, AND ARE PROVIDED 'AS-IS' AND WITHOUT WARRANTY. MSCI NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI.